Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
Relapsed/Refractory Chronic Lymphocytic Leukemia
Type
Interventional
Phase
Phase 1Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

The purpose of the escalation part of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (if reached) as well as establish the safety profile of epcoritamab in patients with R/R CLL. In the expansion part additional patients will be treated with epcoritamab ...

The purpose of the escalation part of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (if reached) as well as establish the safety profile of epcoritamab in patients with R/R CLL. In the expansion part additional patients will be treated with epcoritamab at the RP2D and the the purpose is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab at the RP2D.

Tracking Information

NCT #
NCT04623541
Collaborators
AbbVie
Investigators
Not Provided